Key Takeaways:
Altimmune Inc. (Nasdaq: ALT) announced that 48-week data from its pemvidutide trial in metabolic dysfunction-associated steatohepatitis (MASH) has been selected for the “Best of EASL 2026,” a distinction highlighting its significance ahead of the annual liver congress.
The selection by the European Association for the Study of the Liver (EASL) suggests the late-stage data is viewed as a noteworthy contribution to the scientific program. "A copy of the oral presentation and posters will be available in the Events section of the Altimmune website," the company said in its statement.
The full 48-week efficacy and safety results from the IMPACT Phase 2b trial will be presented orally on May 28. Additional posters include a late-breaking abstract on 24-week fibrosis regression analyzed by digital pathology, a responder analysis using multiple non-invasive tests, and the drug's effect on cardiovascular risk factors over 48 weeks.
The "Best of EASL" recognition is a significant vote of confidence for pemvidutide, potentially de-risking the asset for investors and attracting partners. The drug, a balanced 1:1 glucagon and GLP-1 dual agonist, holds both Fast Track and Breakthrough Therapy designations from the FDA for MASH.
Altimmune will feature its data across one oral and three poster presentations at the EASL Congress 2026 in Barcelona. The main event is the oral presentation by Dr. Mazen Noureddin of Houston Methodist Hospital, which will cover the top-line 48-week results from the IMPACT study.
The presentations are scheduled as follows:
The IMPACT Phase 2b study enrolled 212 participants with biopsy-confirmed MASH and significant fibrosis (stages F2 or F3). Patients were randomized to receive weekly injections of 1.2 mg or 1.8 mg of pemvidutide, or a placebo, for 48 weeks. The trial's primary endpoints, measured at 24 weeks, were MASH resolution or fibrosis improvement.
Pemvidutide is also being developed for alcohol use disorder and alcohol-associated liver disease in separate Phase 2 trials.
The selection for the "Best of EASL" summary deck is a strong positive signal ahead of the full data disclosure. For a company in the highly competitive MASH space, such an honor suggests the results are clinically meaningful and statistically significant, which could have a major impact on the company's valuation and future development plans. Investors will be closely watching the detailed efficacy and safety profile presented on May 28.
This article is for informational purposes only and does not constitute investment advice.
